Positive opinion for Iluvien in France

Article

The Transparency Commission of the French National Health Authority has issued a positive opinion for the reimbursement and hospital listing of Iluvien.

The Transparency Commission of the French National Health Authority has issued a positive opinion for the reimbursement and hospital listing of Iluvien.

The intravitreal implant, developed by Alimera Sciences for the treatment of diabetic macular oedmea (DME), has completed two Phase III clinical trials and demonstrates an improvement in best-corrected visual acuity (BVCA) and an increase in ETDRS eye chart letters.

Professor Gisele Soubrane, clinical investigator for Iluvien, commented, “The Iluvien implant features a sustained-release of the active pharmaceutical agent for up to 36 months, which is in balance with the insidious progression of macular oedema due to long-term diabetes mellitus. The clinical results of the trials were significant; Iluvien provides a new, effective mode for achieving vision improvement."

Dan Myers, Alimera's president and chief executive officer, stated, "We are pleased to receive the CT's positive opinion for reimbursement of Iluvien. We believe this opinion will help us in our discussions with the CEPS pricing committee as we work to make Iluvien available to those suffering from chronic DME in France."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Related Content
© 2025 MJH Life Sciences

All rights reserved.